Sign in

CIK 0001826457

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Monte Rosa Therapeutics, Inc.

Sign in to watch
Ticker
GLUE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 617-949-2643
Business address
321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
Former names
Monte Rosa Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$137
in 1 filing

Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Bowen Matthew −$137 Principal Accounting Officer sold <1% of stake
Date Insider Transaction Shares Price Value Owned after
2026-04-09 Nickson Philip Chief Business & Legal Officer Sale −5,845 $17.69 $103K 55,000
2026-01-05 Nickson Philip Chief Business & Legal Officer Sale −3,155 $15.17 $48K 60,845
2026-01-02 Nickson Philip Chief Business & Legal Officer Grant or award +28,000 64,000
2026-01-02 Nickson Philip Chief Business & Legal Officer Grant or award · Stock Option (Right to Buy) +126,000 126,000
2025-01-02 Nickson Philip Chief Business & Legal Officer Grant or award +36,000 36,000
2025-01-02 Nickson Philip Chief Business & Legal Officer Grant or award · Stock Option (Right to Buy) +161,000 161,000
2024-06-03 Nickson Philip Chief Business & Legal Officer Grant or award · Stock Option (Right to Buy) +40,000 40,000
2024-01-02 Nickson Philip General Counsel Grant or award · Stock Option (Right to Buy) +109,000 109,000
2023-01-03 Nickson Philip General Counsel Grant or award · Stock Option (Right to Buy) +123,650 123,650
2022-03-01 Nickson Philip General Counsel Grant or award · Stock Option (Right to Buy) +70,600 70,600

Page 1 of 1 · 10 trades